At a glance Retatrutide is a triple-hormone agonist (GLP-1, GIP and glucagon) currently in Phase 3 trials it is not yet approved or available to prescribe The most common side effects are gastrointestinal: nausea, diarrhoea, vomiting and constipation, particularly during dose increases In the Phase 2 trial, up to 16% of participants on the highest dose reported nausea, though most cases were mild to moderate A dose-dependent increase in heart rate was observed, peaking around 24 weeks before levelling off Around 7% of participants reported skin-related sensations like tingling or increased sensitivity No serious safety signals have emerged so far, but long-term data from Phase 3 trials is still being collected How retatrutide works Before getting into the specifics, it helps to understand what retatrutide actually does, because the side effect profile follows directly from its mechanism
But this scale is deceptive because if we were to also add the problem of increased cell growth causing decreased longevity the scales would probably be opposite
Nrf2-regulated metabolic pathways indeed include the pentose phosphate pathway and stimulation of enzymes that cooperate with fatty acid biosynthesis [19]
1E, F) 11
Cancer Statistics, 2025 provides data on cancer occurrence and outcomes: The cancer mortality rate continued to decline through 2022, with nearly 4.5 million deaths averted since 1991 because of smoking reductions, earlier detection for some cancers, and improved treatment
